Rothblatt’s Stock Sale Amid Biotech Gains | Business and Finance News

Martine Rothblatt, CEO of United Therapeutics, quietly cashed in $5 million in stock—part of a pre-planned November 2025 strategy—by selling shares she’d acquired via low-cost options, now worth over $530 each. Though insider sales can raise eyebrows, Rothblatt still holds hundreds of millions in company stock, and recent breakthroughs in lung disease treatments keep investor confidence high. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/c43f24ec8dee894c